|Videos|December 13, 2017

NFID Medical Director Shares Stories to Inspire Patients & Providers Alike to Get Flu Shots

William Schaffner, MD, shares stories to motivate patients and health care providers to receive the flu vaccine.

William Schaffner, MD, medical director of the National Foundation for Infectious Diseases, shares stories to motivate patients and health care providers to receive the flu vaccine.

Interview Transcript (modified slightly for readability):

"Educating the public is, of course, what you do in Contagion, and I’m so proud of you for doing that, and [for] helping to educate the profession, also. We have to keep providing good information.

There are a couple of stories that I think we haven’t told about the flu that actually might motivate both providers and patients to get the vaccine. The first is that older people are frailer. After they get influenza, many of them on their recovery are weakened and they never quite get back up to that strong level of functioning in society that they had before they became ill. And that starts their downward slide to disability. Nobody over age 65 wants to become disabled, so we need to tell that message.

Another message, and this is aimed at providers also, is it’s not very well known that influenza sets up an inflammatory state. While we recover from that lung infection, influenza, the inflammatory state remains. And for the several weeks, up to a month or two after flu, patients are definitely at increased risk of heart attacks and strokes, all potentially prevented by vaccination.

So, if providers needed more motivation—preventing heart attacks and strokes with a vaccine, wow! That’s news. Preventing disability? That ought to be news to patients and motivate them to get the vaccine. And mind you, for people aged 65 and older, we have vaccines specially formulated that provide greater protection for them than the standard vaccine. So, they would ask their providers if that’s the right vaccine for them.”


Related to this article

NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 9, 2026
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.